Review



vildagliptin galvus  (Novartis)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Novartis vildagliptin galvus
    The structures of DPP-4 inhibitors used in T2D therapy: ( a ) alogliptin, ( b ) linagliptin, ( c ) saxagliptin, ( d ) sitagliptin, ( e ) <t>vildagliptin.</t> The structures were prepared with Reaxys.
    Vildagliptin Galvus, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vildagliptin galvus/product/Novartis
    Average 90 stars, based on 1 article reviews
    vildagliptin galvus - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome"

    Article Title: Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome

    Journal: Pharmaceutics

    doi: 10.3390/pharmaceutics17060768

    The structures of DPP-4 inhibitors used in T2D therapy: ( a ) alogliptin, ( b ) linagliptin, ( c ) saxagliptin, ( d ) sitagliptin, ( e ) vildagliptin. The structures were prepared with Reaxys.
    Figure Legend Snippet: The structures of DPP-4 inhibitors used in T2D therapy: ( a ) alogliptin, ( b ) linagliptin, ( c ) saxagliptin, ( d ) sitagliptin, ( e ) vildagliptin. The structures were prepared with Reaxys.

    Techniques Used:



    Similar Products

    vildagliptin  (MedChemExpress)
    93
    MedChemExpress vildagliptin
    Vildagliptin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vildagliptin/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    vildagliptin - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    vildagliptin galvus  (Novartis)
    90
    Novartis vildagliptin galvus
    The structures of DPP-4 inhibitors used in T2D therapy: ( a ) alogliptin, ( b ) linagliptin, ( c ) saxagliptin, ( d ) sitagliptin, ( e ) <t>vildagliptin.</t> The structures were prepared with Reaxys.
    Vildagliptin Galvus, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vildagliptin galvus/product/Novartis
    Average 90 stars, based on 1 article reviews
    vildagliptin galvus - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    dpp4 inhibitor vildagliptin  (MedChemExpress)
    93
    MedChemExpress dpp4 inhibitor vildagliptin
    The structures of DPP-4 inhibitors used in T2D therapy: ( a ) alogliptin, ( b ) linagliptin, ( c ) saxagliptin, ( d ) sitagliptin, ( e ) <t>vildagliptin.</t> The structures were prepared with Reaxys.
    Dpp4 Inhibitor Vildagliptin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dpp4 inhibitor vildagliptin/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    dpp4 inhibitor vildagliptin - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    ptc 1 cells  (MedChemExpress)
    93
    MedChemExpress ptc 1 cells
    The structures of DPP-4 inhibitors used in T2D therapy: ( a ) alogliptin, ( b ) linagliptin, ( c ) saxagliptin, ( d ) sitagliptin, ( e ) <t>vildagliptin.</t> The structures were prepared with Reaxys.
    Ptc 1 Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ptc 1 cells/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    ptc 1 cells - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    vildagliptin tablet galvus  (Novartis)
    90
    Novartis vildagliptin tablet galvus
    The structures of DPP-4 inhibitors used in T2D therapy: ( a ) alogliptin, ( b ) linagliptin, ( c ) saxagliptin, ( d ) sitagliptin, ( e ) <t>vildagliptin.</t> The structures were prepared with Reaxys.
    Vildagliptin Tablet Galvus, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vildagliptin tablet galvus/product/Novartis
    Average 90 stars, based on 1 article reviews
    vildagliptin tablet galvus - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    ecs  (Selleck Chemicals)
    92
    Selleck Chemicals ecs
    The structures of DPP-4 inhibitors used in T2D therapy: ( a ) alogliptin, ( b ) linagliptin, ( c ) saxagliptin, ( d ) sitagliptin, ( e ) <t>vildagliptin.</t> The structures were prepared with Reaxys.
    Ecs, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ecs/product/Selleck Chemicals
    Average 92 stars, based on 1 article reviews
    ecs - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier
    vildagliptin  (Selleck Chemicals)
    92
    Selleck Chemicals vildagliptin
    Impact of DPP-IV inhibition on infantile hemangioma-derived endothelial cells (Hem-ECs) in vitro. Hem-ECs treated with increasing <t>vildagliptin</t> (VLDG) concentrations for 24 h ( A ) and 72 h ( B ), respectively. Percent viability with respect to untreated cells (CTRL) is reported as mean ± standard error (SE); * p < 0.05 vs. control. Holm-Sidak’s test. ( C ) Immunoblotting analysis documenting a dose-dependent increase in p21 protein expression in Hem-ECs following VLDG exposure. HSP90 serves as the loading control. Densitometric values normalized vs. control (HSP90) are reported at the bottom of each p21 blot. ( D ) Flow cytometric analysis of Hem-EC proliferation. Gating strategy illustrating the percentage of ki67-positive untreated (CTRL) and VLDG-treated Hem-ECs. The density of scatter dot-plots in positive gate decreases in a dose-dependent manner. Mean fluorescent intensity (MFI) of ki67 labeling is also reported. ( E ) Apoptosis assay, as measured by the cytometric analysis of Annexin V, on Hem-ECs after 72 h exposure to 100 μM and 250 μM VLDG. ( F ) Cell cycle analysis of Hem-ECs after 72 h of VLDG treatment. The percentage of cells in the different phases of the cell cycle was calculated using the Watson Pragmatic Model of FlowJo (v10.8) software.
    Vildagliptin, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vildagliptin/product/Selleck Chemicals
    Average 92 stars, based on 1 article reviews
    vildagliptin - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier
    vildagliptin (galvus® tablet)  (Novartis)
    90
    Novartis vildagliptin (galvus® tablet)
    Impact of DPP-IV inhibition on infantile hemangioma-derived endothelial cells (Hem-ECs) in vitro. Hem-ECs treated with increasing <t>vildagliptin</t> (VLDG) concentrations for 24 h ( A ) and 72 h ( B ), respectively. Percent viability with respect to untreated cells (CTRL) is reported as mean ± standard error (SE); * p < 0.05 vs. control. Holm-Sidak’s test. ( C ) Immunoblotting analysis documenting a dose-dependent increase in p21 protein expression in Hem-ECs following VLDG exposure. HSP90 serves as the loading control. Densitometric values normalized vs. control (HSP90) are reported at the bottom of each p21 blot. ( D ) Flow cytometric analysis of Hem-EC proliferation. Gating strategy illustrating the percentage of ki67-positive untreated (CTRL) and VLDG-treated Hem-ECs. The density of scatter dot-plots in positive gate decreases in a dose-dependent manner. Mean fluorescent intensity (MFI) of ki67 labeling is also reported. ( E ) Apoptosis assay, as measured by the cytometric analysis of Annexin V, on Hem-ECs after 72 h exposure to 100 μM and 250 μM VLDG. ( F ) Cell cycle analysis of Hem-ECs after 72 h of VLDG treatment. The percentage of cells in the different phases of the cell cycle was calculated using the Watson Pragmatic Model of FlowJo (v10.8) software.
    Vildagliptin (Galvus® Tablet), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vildagliptin (galvus® tablet)/product/Novartis
    Average 90 stars, based on 1 article reviews
    vildagliptin (galvus® tablet) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The structures of DPP-4 inhibitors used in T2D therapy: ( a ) alogliptin, ( b ) linagliptin, ( c ) saxagliptin, ( d ) sitagliptin, ( e ) vildagliptin. The structures were prepared with Reaxys.

    Journal: Pharmaceutics

    Article Title: Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome

    doi: 10.3390/pharmaceutics17060768

    Figure Lengend Snippet: The structures of DPP-4 inhibitors used in T2D therapy: ( a ) alogliptin, ( b ) linagliptin, ( c ) saxagliptin, ( d ) sitagliptin, ( e ) vildagliptin. The structures were prepared with Reaxys.

    Article Snippet: In addition, vildagliptin was approved in the European Union in September 2007 (marketed as Galvus ® , developed by Novartis Europharm Limited (London, United Kingdom)) [ , ].

    Techniques:

    Impact of DPP-IV inhibition on infantile hemangioma-derived endothelial cells (Hem-ECs) in vitro. Hem-ECs treated with increasing vildagliptin (VLDG) concentrations for 24 h ( A ) and 72 h ( B ), respectively. Percent viability with respect to untreated cells (CTRL) is reported as mean ± standard error (SE); * p < 0.05 vs. control. Holm-Sidak’s test. ( C ) Immunoblotting analysis documenting a dose-dependent increase in p21 protein expression in Hem-ECs following VLDG exposure. HSP90 serves as the loading control. Densitometric values normalized vs. control (HSP90) are reported at the bottom of each p21 blot. ( D ) Flow cytometric analysis of Hem-EC proliferation. Gating strategy illustrating the percentage of ki67-positive untreated (CTRL) and VLDG-treated Hem-ECs. The density of scatter dot-plots in positive gate decreases in a dose-dependent manner. Mean fluorescent intensity (MFI) of ki67 labeling is also reported. ( E ) Apoptosis assay, as measured by the cytometric analysis of Annexin V, on Hem-ECs after 72 h exposure to 100 μM and 250 μM VLDG. ( F ) Cell cycle analysis of Hem-ECs after 72 h of VLDG treatment. The percentage of cells in the different phases of the cell cycle was calculated using the Watson Pragmatic Model of FlowJo (v10.8) software.

    Journal: International Journal of Molecular Sciences

    Article Title: CD26 Is Differentially Expressed throughout the Life Cycle of Infantile Hemangiomas and Characterizes the Proliferative Phase

    doi: 10.3390/ijms25189760

    Figure Lengend Snippet: Impact of DPP-IV inhibition on infantile hemangioma-derived endothelial cells (Hem-ECs) in vitro. Hem-ECs treated with increasing vildagliptin (VLDG) concentrations for 24 h ( A ) and 72 h ( B ), respectively. Percent viability with respect to untreated cells (CTRL) is reported as mean ± standard error (SE); * p < 0.05 vs. control. Holm-Sidak’s test. ( C ) Immunoblotting analysis documenting a dose-dependent increase in p21 protein expression in Hem-ECs following VLDG exposure. HSP90 serves as the loading control. Densitometric values normalized vs. control (HSP90) are reported at the bottom of each p21 blot. ( D ) Flow cytometric analysis of Hem-EC proliferation. Gating strategy illustrating the percentage of ki67-positive untreated (CTRL) and VLDG-treated Hem-ECs. The density of scatter dot-plots in positive gate decreases in a dose-dependent manner. Mean fluorescent intensity (MFI) of ki67 labeling is also reported. ( E ) Apoptosis assay, as measured by the cytometric analysis of Annexin V, on Hem-ECs after 72 h exposure to 100 μM and 250 μM VLDG. ( F ) Cell cycle analysis of Hem-ECs after 72 h of VLDG treatment. The percentage of cells in the different phases of the cell cycle was calculated using the Watson Pragmatic Model of FlowJo (v10.8) software.

    Article Snippet: After adhesion, Hem-ECs were exposed to various vildagliptin (Selleckchem, Houston, TX, USA; LAF-237) μM concentrations (1, 10, 25, 50, 100, 250, 500, and 1000).

    Techniques: Inhibition, Derivative Assay, In Vitro, Control, Western Blot, Expressing, Labeling, Apoptosis Assay, Cell Cycle Assay, Software